Drug Profile
Research programme: acute myeloid leukaemia therapeutics - Cotinga Pharmaceuticals
Alternative Names: AML tyrosine kinase inhibitors - Cotinga PharmaceuticalsLatest Information Update: 10 Jan 2018
Price :
$50
*
At a glance
- Originator Critical Outcome Technologies
- Developer Cotinga Pharmaceuticals
- Class Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Acute myeloid leukaemia
Highest Development Phases
- No development reported Acute myeloid leukaemia
Most Recent Events
- 08 Jan 2018 Critical Outcome Technologies is now called Cotinga Pharmaceuticals
- 04 Nov 2017 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in Canada (PO)
- 09 Apr 2013 Critical Outcome Technologies selects and patents three drug candidates selected for preclinical studies in Acute myeloid leukaemia